Skip to main content
SpringerLink
Log in

Antiinflammatory treatment and intestinal α1-antitrypsin clearance in active Crohn's disease

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Intestinal α1-antitrypsin clearance was quantified in 17 patients with clinically active Crohn's disease before and after a six-week period of treatment with sulfasalazine and methylprednisolone. Before the study, α1-antitrypsin clearance and, hence, enteric protein loss was elevated as being above control values in 16 patients. After therapy, clearance values decreased in 11 and were normalized in five patients. Serum albumin level was normalized in 11 of 12 patients who had hypoalbuminemia before the study. Clinical condition was improved in all but 1 patient after treatment. There was no close correlation between α1-antitrypsin clearance and disease activity index. These results indicate that antiinflammatory therapy has a beneficial effect on enteric protein loss in Crohn's disease. The measurement of α1-antitrypsin clearance provides a useful adjunctive technique in evaluating intestinal inflammatory activity, and it seems to be of use in following the efficacy of treatment in the course of illness in Crohn's disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beeken WL, Busch HJ, Sylvester DL: Intestinal protein loss in Crohn's disease. Gastroenterology 62:207–215, 1972

    Google Scholar 

  2. Bendixen G, Jarnum S, Soloft J, Westergaard H, Weeke B, Yssing M: IgG and Albumin turnover in Crohn's disease. Scand J Gastroenterol 3:481–489, 1968

    Google Scholar 

  3. Steinfeld JL, Davidson JD, Gordon RS, Greene FE: The mechanism of hypoproteinemia in patients with regional enteritis and ulcerative colitis. Am J Med 29:405–415, 1960

    Google Scholar 

  4. Wetterfors L, Liljedahl SO, Plantin LO, Birke G: Hypoalbuminemia in ulcerative colitis and certain forms of enteritis. Clinical and pathophysiological aspects. Acta Med Scand 174:529–549, 1963

    Google Scholar 

  5. Brassine A: Study of the metabolism of serum-albumin and measurement of the digestive loss of plasmatic proteins during Crohn's disease and ulcerative colitis. Acta Gastroenterol Belg 41:7–17, 1978

    Google Scholar 

  6. Jarnum S, Westergaard H, Yssing M: Quantitation of gastrointestinal protein loss by means of59Fe-labeled dextran. Gastroenterology 55:229–241, 1968

    Google Scholar 

  7. Jarnum S, Jensen KB: Fecal radioiodide excretion following intravenous injection of131I-albumin and125I-immunoglobulin G in chronic inflammatory bowel disease. An aid to topographic diagnosis. Gastroenterology 68:1433–1444, 1975

    Google Scholar 

  8. Jarnum S, Storgaard L, Westergaard H, Jensen KB, Yssing M: Topographic diagnosis of gastrointestinal protein loss by means of radioiodine-labeled albumin and IgG. Scand J Gastroenterol 14:119–121, 1978

    Google Scholar 

  9. Jeejeebhoy KN, Singh B, Mani RS, Sanjana SM: The use of95Nb-labeled albumin in the study of gastrointestinal protein loss. In Physiology and Pathophysiology of Plasma Protein Metabolism. Koblet H, Vesin P, Diggelmann H, Barandun S (eds.), Bern, Huber Verlag, 1964, pp 61–67

    Google Scholar 

  10. Jeffries GH, Holman H, Sleisinger MH: Plasma proteins and the gastrointestinal tract. N Engl J Med 266:652–660, 1962

    Google Scholar 

  11. van Tongeren JH, Eekhout A: Criteria to assess the severity of Crohn's disease and the effect of treatment.In The management of Crohn's Disease. Proceedings of the Workshop on Crohn's Diseas. IT Weteman, AS Peña, CC Booth (eds). Amsterdam, Elsevier, 1976, pp 153–158

    Google Scholar 

  12. Andersen SB, Jarnum S: Detection of abnormal gastrointestinal protein loss by means of59FE-inferon. Lancet 1:1060–1062, 1965

    Google Scholar 

  13. Gordon RS: Exudative enteropathy. Abnormal permeability of the gastrointestinal tract demonstrable with labelled polyvinyl-pyrrolidine. Lancet 1:325–326, 1959

    Google Scholar 

  14. Waldman TA: Gastrointestinal protein loss demonstrated by51Cr-albumin. Lancet 2:121–123, 1961

    Google Scholar 

  15. Waldman TA, Morell GA, Wochner RD, Strober W, Sternlieb J: Measurement of gastrointestinal protein loss using ceruloplasmin labeled with67copper. J Clin Invest 46:10–20, 1976

    Google Scholar 

  16. Crossley JR, Elliot RP: Simple method for diagnosing protein-losing enteropathies. Br Med J 1:428–429, 1977

    Google Scholar 

  17. Florent C, l'Hirondel C, Desmazures C, Giraudeaux V, Bernier JJ: Evaluation of ulcerative colitis and Crohn's disease activity by means of alpha1-antitrypsin intestinal clearance. Gastroenterol Clin Biol 5:193–197, 1981

    Google Scholar 

  18. Karbach U, Ewe K, Bodenstein H: α1-Antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease. Gut 24:718–723, 1983

    Google Scholar 

  19. Bernier JJ, Florent C, Desmazures C, Aymes C, l'Hirondel C: Diagnosis of protein-losing enteropathy by gastrointestinal clearance of α1-antitrypsin. Lancet 2:763–764, 1978

    Google Scholar 

  20. Best W, Becktel JM, Singleton JM, Kern J: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70:439–444, 1978

    Google Scholar 

  21. Florent C, l'Hirondel C, Desmazures C, Aymes C, Bernier JJ: Intestinal clearance of α1-antitrypsin. A sensitive method for the detection of protein-losing enteropathy. Gastroenterology 81:777–780, 1981

    Google Scholar 

  22. Heaney MR, Fields J, Carter RA, Thompson RA, Asquith P: Is fecal α1-antitrypsin excretion a reliable screening test for protein-losing enteropathy? Lancet 2:1161–1162, 1979

    Google Scholar 

  23. Lennard-Jones JE: Sulfasalazine in asymptomatic Crohn's disease. A multicenter trial. Gut 18:69–72, 1977

    Google Scholar 

  24. Smith RC, Rhodes J, Heatley RV, Crosby DL, Rees BI, Jones H, Evans KT, Lawrie BW: Low dose steroids and clinical relapse in Crohn's disease: A controlled trial. Gut 19:606–610, 1978

    Google Scholar 

  25. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, Singleton JW: National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 78:847–869, 1979

    Google Scholar 

  26. Cline MJ, Mecmond KLA: Plasma kinis and cortisol: A possible explanation of the antiinflammatory action of cortisol. Science 153:1135–1138, 1966

    Google Scholar 

  27. Weissmann G, Thomas L: The effect of corticosteroids upon connective tissue and lysosomes. Recent Prog Horm Res 20:215–245, 1964

    Google Scholar 

  28. Floman Y, Zor U: Mechanism of steroid action in inflammation: Inhibition of prostaglandin synthesis and release Prostaglandins 12:403–413, 1976

    Google Scholar 

  29. Heatley RV, Bolton PM, Owen EW: Mesenteric lymphatic obstruction in Crohn's disease. Digestion 20:307–313, 1980

    Google Scholar 

  30. van Hees PAM, van Lier HJJ, van Elteren PH, Driessen WMM, van Hogezand RA, ten Velde GPM, Bakker JH, van Tongeren JHM: Effect of sulfasalazine in patients with active Crohn's disease: A controlled double-blind study. Gut 22:404–409, 1981

    Google Scholar 

  31. Schröder H, Campbell DES: Absorption, metabolism and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 13:539–551, 1972

    Google Scholar 

  32. Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active moiety of sulfasalazine. Lancet 2:892–895, 1977

    Google Scholar 

  33. van Hees PAM, Bakker JH, van Tongeren JHM: Effect of sulfapyridine, 5-amino-salicylic acid and placebo in patients with idiopathic proctitis. A study to determine the active therapeutic moiety of sulfasalazine. Gut 21:632–635, 1980

    Google Scholar 

  34. Butt AA, Collier HOJ, Gardiner PJ, Saeed SA: Effects on prostaglandin biosynthesis of drugs affecting gastrointestinal function. Gut 15:344, 1974

    Google Scholar 

  35. Gould SR: Prostaglandins, ulcerative colitis and sulfasalazine. Lancet 2:988, 1975

    Google Scholar 

  36. Sharon P, Ligumsky M, Rachmilewitz D, Zor U: Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 75:638–640, 1978

    Google Scholar 

  37. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nature (London), New Biol 231:232–235, 1971

    Google Scholar 

  38. Rutgeerts P, Ghoos Y, Vantrappen G, Eyssen H: Ileal dysfunction and bacterial overgrowth in patients with Crohn's disease. Eur J Clin Invest 11:199–206, 1981

    Google Scholar 

  39. Thomas DW, Sinatra FR, Merritt RJ: Random fecal alpha1-antitrypsin concentration in children with gastrointestinal disease. Gastroenterology 80:776–782, 1981

    Google Scholar 

  40. Axelsson CK, Jarnum S: Influence of an elemental diet in chronic inflammatory bowel disease. Digestion 16:77–86, 1977

    Google Scholar 

  41. Logan RFA, Gillon J, Ferrington C, Ferguson A: Reduction of gastrointestinal protein loss by elemental diet in Crohn's disease of the small bowel. Gut 22:383–387, 1981

    Google Scholar 

  42. Kaufmann S, Chalner B, Heimar R, Beeken W: A prospective study of the course of Crohn's disease. Am J Dig Dis 24:269–276, 1979

    Google Scholar 

  43. Sategna-Guidetti C, Boero R, Rutigliano AR, Morello C: Intestinal clearance of α1-antitrypsin in IBD. Scand J Gastroenterol 17(Suppl 78):350, 1982

    Google Scholar 

  44. Flick AL, Steinfeld JL: The effect of fever and corticotropin on thein vivo degradation of albumin in man measured with iodinated human serum albumin. Am J Med 236:65–79, 1958

    Google Scholar 

  45. Rothschild MA, Schreiber SS, Oratz M: The effect of adrenocortical hormones on albumin metabolism studied with albumin-I131. J Clin Invest 37:1229–1235, 1958

    Google Scholar 

  46. Martini GA, Brandes JW: Increased consumption of refined carbohydrates in patients with Crohn's disease. Klin Wochenschr 54:367–371, 1976

    Google Scholar 

  47. Goodman M, Skinner J, Truelove S: Abnormalities in the apparently normal bowel mucosa in Crohn's disease. Lancet 1:275–276, 1976

    Google Scholar 

  48. Dyer N, Stansfield A, Dawson A: The value of rectal biopsy in the diagnosis of Crohn's disease. Scand J Gastroenterol 5:491–496, 1970

    Google Scholar 

  49. Ruddel W, Lovell D, Blendis L: Bowel mucosa in Crohn's disease. Lancet 1:539–540, 1976

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik der Universität Mainz, Langenbeckstraße 1, D-6500, Mainz, FRG

    U. Karbach MD,  K. Ewe MD & H. Dehos

Authors
  1. U. Karbach MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Ewe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Dehos
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by Deutsche Forschungsgemeinschaft grant EW 4/15-3.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karbach, U., Ewe, K. & Dehos, H. Antiinflammatory treatment and intestinal α1-antitrypsin clearance in active Crohn's disease. Digest Dis Sci 30, 229–235 (1985). https://doi.org/10.1007/BF01347889

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01347889

Keywords

Search

Navigation